Please select the option that best describes you:
Topics:
Breast Cancer • Medical Oncology • Triple negative • Residual disease • Breast Cancer, Non-metastatic
How would you treat a patient with TNBC with a residual strongly PR+, ER- breast mass on mastectomy after neoadjuvant KEYNOTE 522 based chemoimmunotherapy?
Would you consider using endocrine therapy, pembrolizumab, capecitabine, or CDK 4/6 inhibitor?
Answer from: Medical Oncologist at Community Practice
Assuming that the original tissue biopsy was accurate as triple negative tumor, this may be a scenario with heterogenous tumor biology where initial biopsy sampling did not catch PR positivity, and following neoadjuvant therapy PR positive tumor clones remained as dominant residual disease. I would ...
On a similar note, I just saw a woman post op who ...
The low PR expression wouldn't dissuade me from tr...
I respectfully disagree: The patient is PR positiv...
I think that any hormone sensitivity is important....
Would recommend both adjuvant pembro and hormone b...